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How can an ex-orphan be adopted? Is it possible to do so by attributing to it a key endogenous ligand
that regulates its central functions? In the recent issue of Cell, Chakravarthy et al. attempted to answer
this question by characterizing a new physiologically relevant ligand for the ex-orphan receptor peroxisome
proliferator activated receptor alpha (PPARa).
PPARs form a subfamily of nuclear
hormone receptors comprising three
isotypes: PPARa, PPARb/d, and PPARg.
These transcription factors are drug
targets in the context of the widespread
human diseases diabetes (PPARg) and
dyslipidemia (PPARa), and their main
physiological roles are tomodulate energy
metabolism and inflammatory pathways
in response to dietary and endogenous
signals.
To understand the concept of the
orphan receptor, one has to look back
a couple of decades to when the different
members of the nuclear hormone receptor
family were cloned. The first to be identi-
fied were those mediating responses to
circulating steroid and thyroid hormones.
Mainly based on sequence homology
screens, the gene family expanded up to
48 members in humans. In most cases,
no natural ligand was known to bind to
the newly identified receptors. Therefore,
they were categorized as orphan recep-
tors. This was the case for PPARs in the
early 1990s (Issemann and Green, 1990;
Dreyer et al., 1992).
Then started the difficult quest for
endogenous ligands for PPARs. The
adoption of orphan nuclear receptors is
not easy. The ideal candidate ligand
must be able to occupy the ligand-binding
pocket of the receptor. By doing so, it trig-
gers a conformational change in the
receptor that switches its association
with co-repressors to co-activators. Ulti-
mately, this culminates in the recruitment
and activation of the transcriptional
machineryat thepromoterof targetgenes.
In the past decade, a large number of
physiologically relevant molecules have
been proposed to be endogenous PPAR
ligands. They are mostly unsaturated or
polyunsaturated fatty acids and eicosa-
noids, and are often required at micro-
molar concentrations to achieve PPAR
activation (Michalik et al., 2006). This low
affinity is compatible with the serum levels
of these ligands, but cellular concentra-
tions have not been clearly established
and, therefore, it is still not clear how
many endogenous molecules are avail-
able in sufficient amounts in the cell
nucleus to trigger PPAR-dependent tran-
scription. Recently, a few reports have
pointed to natural molecules with a nano-
molar affinity for PPARs (Davies et al.,
2001; Lin et al., 1999; Shaw et al., 2003;
Schopfer et al., 2005). However, these
findings have not shed new light on how
PPARs, and especially PPARa, respond
to dietary stimuli to maintain energy
homeostasis, which is believed to be one
of the major functions of PPARs, with
obvious clinical implications.
Chakravarthy et al. (2009) have
advanced the field by identifying an
endogenous ligand with a nanomolar
affinity for PPARa. It controls hepatic
PPARa functions and its production is
influencedby thediet. How this new ligand
was identified is probably as remarkable
as the finding itself. The authors tested
the hypothesis raised by their previous
work according to which fatty acid syn-
thase (FAS) is implicated in PPARa-ligand
production in the liver (Chakravarthy et al.,
2005). They produced mice expressing
a FLAG-tagged version of PPARa in the
liver, pulled down the receptor, and identi-
fied lipid species bound to it by mass
spectrometry. They compared the results
obtained when the PPARa-associated
lipids were purified from normal liver
with those obtained from liver depleted
of FAS (FASKOL mice). They identified
the phospholipid 1-palmitoyl-2-oleoyl-
sn-glycerol-3-phosphocholine (16:0/18:1
GPC) as the sole species to be associated
with PPARa in a FAS-dependent manner.
It binds to PPARa and is displaced by
a potent synthetic PPARa agonist, which
suggests interaction with the ligand-
binding pocket. However, information is
lacking on the atomic interactions of the
phospholipid within the PPARa ligand-
binding domain. The best evidence that
16:0/18:1 GPC functions as a PPARa
ligand in vivo is that it activates transcrip-
tion in a PPARa-dependent manner
when perfused into the liver through the
portal vein.
The way in which the availability of the
phospholipid ligand for PPARa might be
regulated is important. FAS yields palmi-
tate, following which 16:0/18:1 GPC is
thought to be generated through the diac-
ylglycerol intermediate and choline-etha-
nolamine phosphotransferase-1 (CEPT1)
activity in the endoplasmic reticulum and
the nucleus (Figure 1). In support of this
proposition, the depletion of CEPT1 either
in hepatoma cell lines or in the whole
liver results in decreased PPARa target
gene transcription, which is restored to
a normal level in cells treated with 16:0/
18:1 GPC. In brief, the key finding of the
Cell paper is that liver FAS and CEPT1
regulate PPARa functions by producing
a potent PPARa agonist. This opens new
perspectives but, in parallel, also poses
new questions.
PPARa is known to promote gluconeo-
genesis. Importantly, it is now even more
tightly linked to carbohydrate signaling,
since carbohydrates indirectly stimulate
PPARa activity by upregulating FAS and
thus influence lipid metabolism. There-
fore, in addition to lipid-sensing at the
initiation of PPARa activity, there is carbo-
hydrate-sensing as well, which is rather
unexpected. One may argue that the
mechanism of PPARa activation by 16:0/
18:1 GPC is marginal and only operates
when food is rich in sugars and poor in
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lipids. In line with this thought, FASKOL
mice develop a fatty liver phenotype on
a fat-free diet (no 16:0/18:1 GPC and no
FA available as ligands), but not on
a normal fat-containing diet (Chakravar-
thy et al., 2005). This would make sense
if, as has been proposed, free FA released
by peripheral tissues during fasting, which
enter the liver by the artery, are not able to
activate PPARa. Only ‘‘new fat,’’ either
from the diet or from FAS-dependent neo-
synthesis, would produce PPARa ligands,
not the ‘‘old fat’’ recruited from peripheral
stores (Chakravarthy et al., 2005). If this is
true, FAS-mediated production of 16:0/
18:1 GPCwould stimulate PPARa-depen-
dent pathways in the absence of sufficient
ligands provided by the diet. This would
ensure energy balance under fat-poor
dietary conditions (Figure 1).
Another interestingavenuemayopenas
our knowledge of the synthesis of endog-
enous PPAR ligands grows. It should
become possible to activate PPARs
selectively in an organ- and isotype-
specific manner, which should enable
therapeutic strategies to minimize the
side effects of broad PPAR activation.
Enhancing FAS, for instance, is likely to
influence the PPARa transcriptome selec-
tively, as 16:0/18:1 GPC does not bind to
PPARg and only weakly to PPARb/d.
Finally, since Chakravarthy et al. (2009)
identified numerous lipids that are as-
sociated with PPARa, but in a FAS-indep-
endent manner, the possibility exists,
although not likely, that several lipids
might bind simultaneously to the same
PPARa molecule in a so far unknown
way. Could some kind of integration of
these signals take place at the level of
combinatorial ligand binding?
One important question remains. The
production of 16:0/18:1 GPC is controlled
by FAS and thus its interaction with
PPARa increases when FAS is upregu-
lated by a carbohydrate-rich diet, which
necessarily requires feeding. However,
the expression of PPARa is circadian
(Lemberger et al., 1996), with little PPARa
in the fed state, and an increase during
fasting, coinciding with the need for FA
oxidation to maintain the energy balance.
Since 16:0/18:1 GPC production and
peak of PPARa activity are antiphasic,
one could postulate that if FAS is essential
for producing the PPARa ligand, addi-
tional regulation is required to present
the ligand to PPARa when needed. Alter-
natively, 16:0/18:1 GPC and other already
known PPARa ligands may operate under
different temporal and physiological
conditions.
In conclusion, much remains to be
discovered in the field of PPAR-ligand
production, and future studies will
contribute both to a better appreciation
of the functions of PPARs and their use
as drug targets in different metabolic
deregulations.
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Figure 1. Routes to PPARa Activation in the Liver
Simplified pathways leading to PPARa ligand (in green) production are presented.
(1) Dietary fatty acids activate PPARa.
(2) On no fat diet, FAS and CEPT1 control the production of 16:0/18:1 GPC that activates PPARa.
Activation of PPARa results in the transcriptional regulation of numerous genes, the PPARa transcriptome,
which contributes to maintaining the energy balance in part through the promotion of mitochondrial and
peroxisomal beta-oxidation of fatty acids.
CEPT1, choline-ethanolamine phosphotransferase 1; DAG, diacyglycerol; FA, fatty acids; VLDL, very low
density lipoprotein.
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